)

BioCryst Pharmaceuticals (BCRX) investor relations material
BioCryst Pharmaceuticals M&A Announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Deal rationale and strategic fit
Acquisition adds navenibart, a late-stage, long-acting injectable HAE therapy, supporting a rare disease growth strategy and double-digit revenue growth over the next decade.
Expands the HAE portfolio with both oral and injectable therapies, covering a full spectrum of patient preferences and addressing unmet needs for less frequent dosing.
Seamlessly integrates into and complements the existing HAE franchise, leveraging established commercialization infrastructure.
Accelerates product diversification and reinforces commitment to the HAE community.
Combined portfolio expected to transform growth profile and reinforce leadership in HAE.
Financial terms and conditions
Total enterprise value of $700 million and implied aggregate equity value of $920 million, with Astria shareholders receiving $8.55 in cash and 0.59 BioCryst shares per Astria share, implying $13.00 per share and a 53% premium to prior close.
Astria stockholders will own about 15% of the combined company.
The acquisition will be financed through a mix of equity, cash on hand, and a Blackstone facility ($400–$550 million).
Sale of the European business and retirement of $200 million Pharmakon debt improves the balance sheet.
Transaction expected to be significantly accretive to operating profit in the first full year after navenibart's launch.
Synergies and expected cost savings
Significant operational and long-term synergies expected, leveraging existing commercialization infrastructure.
Minimal incremental SG&A investment anticipated due to established commercial engine.
Enhanced financial profile with strong cash flow generation and profitability maintained post-transaction.
Accelerated revenue from navenibart projected to boost earnings growth well into the next decade.
Next BioCryst Pharmaceuticals earnings date

Next BioCryst Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage